Associated Press, February 18, 2013. A new study reports that hip replacements are slightly more likely to fail in women than in men. Dr. Zuckerman states, “this is the first step in what has to be a much longer-term strategy to figure out why women have worse experiences.”
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Study Suggests Women Have Higher Risk of Hip Implant Failure
The JAMA Network, February 18, 2013. A study in JAMA shows that women have a higher risk of implant failure than men following total hip replacement. In a commentary, NRC President Diana Zuckerman stresses that long-term comparative effectiveness data would enable patients and their physicians to choose the hip devices and surgical techniques that are most likely to be successful for a longer period.
Read More »Metal Hip Implants Face Tighter Controls
Wall Street Journal, January 18, 2013. Diana Zuckerman, president of the National Research Center for Women & Families, said: “There are so many shortcuts at the FDA device center that they often take a shortcut and approve a product with minimal safety testing.”
Read More »J&J Bedaquline and the Evolving Role for Accelerated Approval: Confirming Safety, Not Efficacy?
FDA Beat, December 4, 2012. Discussions during an advisory committee review Janssen’s TB drug bedaquiline showed some interesting thinking around accelerated approval and how much uncertainty can be acceptable—especially when it comes to safety. Yttri warned called “approval of drugs based on the promise of benefit” a “dangerous practice.”
Read More »No Need for Skin Preps to Be Sterile, FDA Told
MedPage Today, December 13, 2012. Requiring that antiseptic skin preparation products be sterile — a standard not currently mandated by the FDA — is unnecessary and wouldn’t produce a dramatic drop in infections, manufacturers, clinicians, and policy analysts told the FDA Wednesday. “We need to have better communication that a product is not sterile,” Dr. Jennifer Yttri said, adding that could come from product labeling.
Read More »